AxoGen, Inc. (AXGN)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, AxoGen, Inc. currently loses $2.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
AxoGen, Inc. topped consensus in the second fiscal quarter of 2026, reporting revenue of $69.7 million against a $67.1 million estimate, +3.9%, when it reported results on July 29, 2026. Revenue rose 23.1% from $56.7 million a year ago, with the U.S. market carrying nearly all of the quarter at about $69.0 million. Gross profit came to about $50.7 million, with gross margin near 73%, while operating margin was about -3% as operating income came in at about -$2.2 million. Adjusted EPS was $0.12, up 0.0% from a year ago, and the company posted a net loss of about $1.5 million versus net income of about $579,000 a year ago. Operating cash flow was about $1.5 million. Consensus for the next period calls for EPS of $0.14 on revenue of $73.2 million.
About AxoGen, Inc.
AxoGen, Inc. develops and sells healthcare products for repairing injured or severed peripheral nerves and trades on the NASDAQ under AXGN. In FY2025, the company generated $225.2 million in revenue from a portfolio of surgical nerve repair and soft-tissue products used by clinicians in reconstructive procedures.
Today's Snapshot
AXGN closed 1.2% higher at 47.27. AxoGen agreed to buy BioCircuit Technologies, a medical-device maker with FDA-approved NerveTape for sutureless nerve repair.
Trading Volume
Below 10d avg (760.9K)
638.8K
vs S&P 500 Today
Outperforming Market
+1.72%
Updated: September 10, 2026 at 12:04 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$36.93 - $48.41Buy
- RSI (14)48.42Neutral
- Stochastic %K (14, 3, 3)28.15Neutral
- MACD Level (12, 26)0.68Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.